Syndax (SNDX) Q2 Revenue Jumps 986%
Syndax Pharmaceuticals (NASDAQ:SNDX), a biopharmaceutical company specializing in oncology therapeutics, reported its second-quarter 2025 earnings on August 4, 2025. The most notable news was its substantial GAAP revenue growth, driven primarily by commercial traction for its newly launched cancer products, Revuforj and Niktimvo. Revenue (GAAP) reached $38.0 million and surpassing Wall Street's GAAP estimate of $26.8 million by $11.2 million (41.8%). The company also reported a GAAP net loss per share of $(0.83), a narrower GAAP loss than the analyst consensus for a $(1.02) loss. Overall, the quarter reflected commercial momentum, effective product launches, and strong physician uptake, with continued investments in future development and scale-up.
Source: Analyst estimates for the quarter provided by FactSet.
Syndax Pharmaceuticals develops and commercializes therapies for cancer, focusing on first-in-class and best-in-class medicines. Its core strategy centers on bringing innovative oncology drugs with high unmet medical need to market and expanding their uses through clinical trials and regulatory approvals.
Source Fool.com
Syndax Pharmaceuticals Inc Aktie
Noch keine eindeutige Richtung: Syndax Pharmaceuticals Inc mit zu wenigen Einschätzungen.
Für Syndax Pharmaceuticals Inc sieht die Community ein Kursziel von 25 €, was eine erhebliche Steigerung um über 50% gegenüber dem aktuellen Kurs von 13.5 € bedeutet.
